Welcome to our dedicated page for Cellyan Biotechnology Co. SEC filings (Ticker: HKPD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Cellyan Biotechnology Co., Ltd. filings document the foreign private issuer’s OTC pharmaceutical cross-border e-commerce supply chain operations, public-company governance, and capital structure. Form 6-K reports include interim consolidated financial statements, operating and financial review materials, and disclosures related to the company’s Class A ordinary shares.
The filing record also covers annual general meeting materials, board and officer changes, independent director appointments, amended constitutional documents, an equity incentive plan, share repurchase and Class B ordinary share matters, Nasdaq minimum bid-price compliance notices, and financing arrangements involving units, warrants, and resale registration rights.
Hong Kong Pharma Digital Technology Holdings Limited (HKPD) reports fiscal results and an extensive risk disclosure in its Form 20-F. The company completed a 1-for-10 share subdivision that increased issued shares to 11,000,000 (11,000 par units reported) and completed an IPO. Consolidated revenue lines shown in the filing include totals such as $20,313,818 and operating segments with revenue amounts like $7,511,591 and $6,217,798. The company recorded a net profit of $1,329,717 for one reported year and basic earnings per share of $0.180. Major shareholders and insider holdings are disclosed: the group of directors and officers hold 56.77% beneficially; Lap Sun Wong is identified as CEO and Chairman and retains controlling voting power. The filing lists extensive regulatory, geopolitical and operational risks, including concentration of customers and suppliers, IT and data governance risks, potential impact of PRC/Hong Kong regulation, possible Nasdaq listing pressures (past share price under $1 and delisting risk), and dependence on HK subsidiaries for cash distributions. The report also discloses material leases, licenses, and bank borrowings and notes key operating costs such as transportation and storage.